Jilin Province Xidian Pharmaceutical Sci-Tech Development (301130.SZ): Sodium hyaluronate eye drops supplementary application for drug approval granted.

Jilin Province Xidian Pharmaceutical Sci-Tech Development (301130.SZ) announced that the company recently received a "Drug Supplement Application Approval Notice" for its sodium hyaluronate eye drops issued by the National Medical Products Administration. After review, the application for this product meets the relevant requirements for drug registration. In accordance with the "Measures for the Administration of Changes after Drug Marketing (Trial)", the applicant for the marketing approval of this product has been changed from "Long Jichuan (Ningxia) Medical Technology Development Co., Ltd. (Address: No. 56, Phase 2, Hengchenghuayuan, Suyin Industrial Park, Xingqing District, Yinchuan City, Ningxia Hui Autonomous Region)" to "Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. (Address: No. 777 Xidian Street, Panshi Economic Development Zone, Jilin Province)", without changing the drug approval number. The transferred drug's production site, prescription, production process, quality standards, etc. remain consistent with the original drug, without any changes. After passing the compliance inspection of drug production quality management standards and meeting the requirements for product release, the transferred drug can be marketed for sale. The approval of this product further enriches the company's product line, helping to enhance the company's product market competitiveness. The approval of this product will have a positive impact on the company's future performance.